Health4 months ago
BioMarin Halts Development of AAT Deficiency Drug BMN 349
BioMarin Pharmaceutical has officially announced the termination of its development for BMN 349, an investigational oral drug aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). This genetic...